TY - JOUR
T1 - Irradiation of the subventricular zone and subgranular zone in high- and low-grade glioma patients
T2 - an atlas-based analysis on overall survival
AU - Bruil, Danique E.
AU - David, Szabolcs
AU - Nagtegaal, Steven H.J.
AU - De Sonnaville, Sophia F.A.M.
AU - Verhoeff, Joost J.C.
N1 - Publisher Copyright: © 2022 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Background: Neural stem cells in the subventricular zone (SVZ) and subgranular zone (SGZ) are hypothesized to support growth of glioma. Therefore, irradiation of the SVZ and SGZ might reduce tumor growth and might improve overall survival (OS). However, it may also inhibit the repair capacity of brain tissue. The aim of this retrospective cohort study is to assess the impact of SVZ and SGZ radiotherapy doses on OS of patients with high-grade (HGG) or low-grade (LGG) glioma. Methods: We included 273 glioma patients who received radiotherapy. We created an SVZ atlas, shared openly with this work, while SGZ labels were taken from the CoBrA atlas. Next, SVZ and SGZ regions were automatically delineated on T1 MR images. Dose and OS correlations were investigated with Cox regression and Kaplan-Meier analysis. Results: Cox regression analyses showed significant hazard ratios for SVZ dose (univariate: 1.029/Gy, P <. 001; multivariate: 1.103/Gy, P =. 002) and SGZ dose (univariate: 1.023/Gy, P <. 001; multivariate: 1.055/Gy, P <. 001) in HGG patients. Kaplan-Meier analysis showed significant correlations between OS and high-/low-dose groups for HGG patients (SVZ: respectively 10.7 months (>30.33 Gy) vs 14.0 months (<30.33 Gy) median OS, P =. 011; SGZ: respectively 10.7 months (>29.11 Gy) vs 15.5 months (<29.11 Gy) median OS, P <. 001). No correlations between dose and OS were found for LGG patients. Conclusion: Irradiation doses on neurogenic areas correlate negatively with OS in patients with HGG. Whether sparing of the SVZ and SGZ during radiotherapy improves OS, should be subject of prospective studies.
AB - Background: Neural stem cells in the subventricular zone (SVZ) and subgranular zone (SGZ) are hypothesized to support growth of glioma. Therefore, irradiation of the SVZ and SGZ might reduce tumor growth and might improve overall survival (OS). However, it may also inhibit the repair capacity of brain tissue. The aim of this retrospective cohort study is to assess the impact of SVZ and SGZ radiotherapy doses on OS of patients with high-grade (HGG) or low-grade (LGG) glioma. Methods: We included 273 glioma patients who received radiotherapy. We created an SVZ atlas, shared openly with this work, while SGZ labels were taken from the CoBrA atlas. Next, SVZ and SGZ regions were automatically delineated on T1 MR images. Dose and OS correlations were investigated with Cox regression and Kaplan-Meier analysis. Results: Cox regression analyses showed significant hazard ratios for SVZ dose (univariate: 1.029/Gy, P <. 001; multivariate: 1.103/Gy, P =. 002) and SGZ dose (univariate: 1.023/Gy, P <. 001; multivariate: 1.055/Gy, P <. 001) in HGG patients. Kaplan-Meier analysis showed significant correlations between OS and high-/low-dose groups for HGG patients (SVZ: respectively 10.7 months (>30.33 Gy) vs 14.0 months (<30.33 Gy) median OS, P =. 011; SGZ: respectively 10.7 months (>29.11 Gy) vs 15.5 months (<29.11 Gy) median OS, P <. 001). No correlations between dose and OS were found for LGG patients. Conclusion: Irradiation doses on neurogenic areas correlate negatively with OS in patients with HGG. Whether sparing of the SVZ and SGZ during radiotherapy improves OS, should be subject of prospective studies.
KW - glioma
KW - overall survival
KW - radiotherapy
KW - subgranular zone
KW - subventricular zone
UR - http://www.scopus.com/inward/record.url?scp=85134955688&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/noajnl/vdab193
DO - https://doi.org/10.1093/noajnl/vdab193
M3 - Article
C2 - 35128399
SN - 2632-2498
VL - 4
JO - Neuro-oncology advances
JF - Neuro-oncology advances
IS - 1
M1 - vdab193
ER -